Bacillus anthracis diagnostic detection and rapid antibiotic susceptibility determination using 'bioluminescent' reporter phage

Journal of Microbiological Methods

Volumn 95, Issue 2, 2013, Pages 156-161

  Schofield, David A ^a   Sharp, Natasha J ^a   Vandamm, Joshua ^a   Molineux, Ian J ^b   Spreng, Krista A ^c   Rajanna, Chythanya ^d   Westwater, Caroline ^e   Stewart, George C ^c  

^a Guild Associates Inc   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anthrax; Bacillus anthracis; Bioluminescence; Detection; Diagnosis; Reporter phage

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM DETECTION; BIOLUMINESCENCE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; REPORTER PHAGE; SPECIES DIFFERENCE;

ANTHRAX; BACILLUS ANTHRACIS; BIOLUMINESCENCE; DETECTION; DIAGNOSIS; REPORTER PHAGE;

BACILLUS ANTHRACIS; BACILLUS CEREUS; BACTERIOPHAGES; DRUG RESISTANCE, BACTERIAL; GENES, REPORTER; HUMANS; LUMINESCENT MEASUREMENTS; SPECIES SPECIFICITY;

EID: 84884146299     PISSN: 01677012     EISSN: 18728359     Source Type: Journal    
DOI: 10.1016/j.mimet.2013.08.013     Document Type: Article

References (40)

1. Abshire T.G., Brown J.E., Ezzell J.W. Production and validation of the use of gamma phage for identification of Bacillus anthracis. J. Clin. Microbiol. 2005, 43:4780-4788.
2. Banaiee N., Bobadilla-Del-Valle M., Bardarov S., Riska P.F., Small P.M., Ponce-De-Leon A., Jacobs W.R., Hatfull G.F., Sifuentes-Osornio J. Luciferase reporter mycobacteriophages for detection, identification, and antibiotic susceptibility testing of Mycobacterium tuberculosis in Mexico. J. Clin. Microbiol. 2001, 39:3883-3888.
3. Bartlett J.G., Inglesby T.V., Borio L. Management of anthrax. Clin. Infect. Dis. 2002, 35:851-858.
4. Beatty M.E., Ashford D.A., Griffin P.M., Tauxe R.V., Sobel J. Gastrointestinal anthrax: review of the literature. Arch. Intern. Med. 2003, 163:2527-2531.
5. Bell C.A., Uhl J.R., Hadfield T.L., David J.C., Meyer R.F., Smith T.F., Cockerill F.R. Detection of Bacillus anthracis DNA by LightCycler PCR. J. Clin. Microbiol. 2002, 40:2897-2902.
6. Bottone E.J. Bacillus cereus, a volatile human pathogen. Clin. Microbiol. Rev. 2010, 23:382-398.
7. Brown E.R., Cherry W.B. Specific identification of Bacillus anthracis by means of a variant bacteriophage. J. Infect. Dis. 1955, 96:34-39.
8. Clinical Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard-Eighth Edition 2009.
9. Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement 2010.
10. Damgaard P.H., Granum P.E., Bresciani J., Torregrossa M.V., Eilenberg J., Valentino L. Characterization of Bacillus thuringiensis isolated from infections in burn wounds. FEMS Immunol. Med. Microbiol. 1997, 18:47-53.
11. De Siano T., Padhi S., Schaffner D.W., Montville T.J. Growth characteristics of virulent Bacillus anthracis and potential surrogate strains. J. Food Prot. 2006, 69:1720-1723.
12. Edwards K.A., Clancy H.A., Baeumner A.J. Bacillus anthracis: toxicology, epidemiology and current rapid-detection methods. Anal. Bioanal. Chem. 2006, 384:73-84.
13. FDA FDA approved anthrax detection kit. FDA news Device Daily Bulletin 2005, 2:241.
14. Fouet A., Mesnage S. Bacillus anthracis cell envelope components. Curr. Top. Microbiol. Immunol. 2002, 271:87-113.
15. Friedlander A.M., Welkos S.L., Pitt M.L.M., Ezzell J.W., Worsham P.L., Rose K.J., Ivins B.E., Lowe J.R., Howe G.B., Mikesell P., Lawrence W.B. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 1993, 167:1239-1242.
16. Greenfield R.A., Bronze M.S. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov. Today 2003, 8:881-888.
17. Inglesby T.V., O'Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., Gerberding J., Hauer J., Hughes J., McDade J., Osterholm M.T., Parker G., Perl T.M., Russell P.K., Tonat K. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287:2236-2252.
18. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., Tapper M., Fisk T.L., Zaki S., Popovic T., Meyer R.F., Quinn C.P., Harper S.A., Fridkin S.K., Sejvar J.J., Shepard C.W., McConnell M., Guarner J., Shieh W.-J., Malecki J.M., Gerberding J.L., Hughes J.M., Perkins B.A. Bioterrorism-related inhalational Anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 2001, 7:933-944.
19. Khan A.S., Swerdlow D.L., Juranek D.D. Precautions against biological and chemical terrorism directed at food and water supplies. Public Health Rep. 2001, 116:3-14.
20. Klee S.R., Nattermann H., Becker S., Urban-Schriefer M., Franz T., Jacob D., Appel B. Evaluation of different methods to discriminate Bacillus anthracis from other bacteria of the Bacillus cereus group. J. Appl. Microbiol. 2006, 100:673-681.
21. Koehler T.M. Bacillus anthracis genetics and virulence gene regulation. Curr. Top. Microbiol. Immunol. 2002, 271:143-164.
22. Lincoln R.E., Hodges D.R., Klein F., Mahlandt B.G., Jones W.I., Haines B.W., Rhian M.A., Walker J.S. Role of the lymphatics in the pathogenesis of anthrax. J. Infect. Dis. 1965, 115:481-494.
23. Lingenfelter B., Ngan V., Fowden S., Rink C., Zharkikh L., Gundry C., Kurrle E., Hanson J., Francesconi S.C., Crawford R., Zapor M., Conger N., Varey S., Hulihan T., Lyons W., Monteville M., Klena J., Sanders J.W., Nakhla I., Sheif M., Karaszkiewicz J., Teng D. An FDA Cleared In Vitro Diagnostic (IVD) Real-Time PCR System for Detection of Bacillus anthracis 2006, American Society for Microbiology General Meeting, Orlando, Florida.
24. Loveless B.M., Yermakova A., Christensen D.R., Kondig J.P., Heine H.S., Wasieloski L.P., Kulesh D.A. Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis. Mol. Cell. Probes 2010, 24:154-160.
25. Makino S., Uchida I., Terakado N., Sasakawa C., Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J. Bacteriol. 1989, 171:722-730.
26. McCloy E.W. Studies on a lysogenic Bacillus strain. A bacteriophage specific for Bacillus anthracis. J. Hyg. 1951, 50:114-125.
27. Meynell E., Meynell G.G. The roles of serum and carbon dioxide in capsule formation by Bacillus anthracis. J. Gen. Microbiol. 1964, 34:153-164.
28. Peker E., Cagan E., Dogan M., Kilic A., Caksen H., Yesilmen O. Periorbital cellulitis caused by Bacillus thuringiensis. Eur. J. Ophthalmol. 2010, 20:243-245.
29. Piuri M., Jacobs W.R.J., Hatfull G.F. Fluoromycobacteriophages for rapid, specific, and sensitive antibiotic susceptibility testing of Mycobacterium tuberculosis. PLoS One 2009, 4:e4870.
30. Schofield D.A., Westwater C. Phage-mediated bioluminescent detection of Bacillus anthracis. J. Appl. Microbiol. 2009, 107:468-478.
31. Schofield D.A., Sharp N.J., Westwater C. Phage-based platforms for the clinical detection of human bacterial pathogens. Bacteriophage 2012, 2:105-121.
32. Schuch R., Fischetti V.A. Detailed genomic analysis of the Wbeta and gamma phages infecting Bacillus anthracis: implications for evolution of environmental fitness and antibiotic resistance. J. Bacteriol. 2006, 188:3037-3051.
33. Scorpio A., Chabot D.J., Day W.A., O'Brien D.K., Vietri N.J., Itoh Y., Mohamadzadeh M., Friedlander A.M. Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob. Agents Chemother. 2007, 51:215-222.
34. Shafazand S., Doyle R., Ruoss S., Weinacker A., Raffin T.A. Inhalational anthrax: epidemiology, diagnosis, and management. Chest 1999, 116:1369-1376.
35. Smartt A.E., Ripp S. Bacteriophage reporter technology for sensing and detecting microbial targets. Anal. Bioanal. Chem. 2011, 400:991-1007.
36. Sobel J., Khan A.S., Swerdlow D.L. Threat of a biological terrorist attack on the US food supply: the CDC perspective. Lancet 2002, 359:874-880.
37. US Army Medical Research Institute of Infectious Diseases Anthrax test, developed by army and CDC, receives FDA approval. Science Daily 2005.
38. Weigel L.M., Sue D., Michel P.A., Kitchel B., Pillai S.P. A rapid antimicrobial susceptibility test for Bacillus anthracis. Antimicrob. Agents Chemother. 2010, 54:2793-2800.
39. Wilson A.C., Soyer M., Hoch J.A., Perego M. The bicarbonate transporter is essential for Bacillus anthracis lethality. PLoS Pathog. 2008, 4:e1000210.
40. Woods J.B. USAMRIID's Management of Biological Casualties Handbook 2005.